Navigation Links
Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture

(WASHINGTON, July 22, 2014) The American Society of Hematology (ASH) will honor Tomas Ganz, MD, PhD, of the University of California Los Angeles with the 2014 E. Donnall Thomas Lecture for his groundbreaking research in iron homeostasis, including the discovery of the iron-regulatory hormone hepcidin and investigation of its roles in iron metabolism. This award, named after the Nobel Prize Laureate and past Society president E. Donnall Thomas, MD, recognizes pioneering research achievements in hematology that have represented a paradigm shift or significant discovery in the field.

Dr. Ganz will present his lecture, "Iron, Erythropoiesis, and Host Defense: A Mnage Trois," at 9:00 a.m. on Monday, December 8, at the 56th ASH Annual Meeting and Exposition in San Francisco. His lecture will explore the advances in understanding of homeostatic iron regulation and the iron-regulatory responses to the challenges of acute hemorrhage and acute infection. During his lecture, Dr. Ganz will discuss iron deficiency anemia and anemia of inflammation and will expand upon how their frequency may reflect an evolutionary compromise to provide sufficient iron for essential processes while avoiding the tendency of iron to promote microbial infections and cause tissue injury. He will further elucidate insights into several components of iron regulation and response and discuss how the hormone hepcidin is regulated by erythroferrone, interleukin-6, and, to a lesser extent, other cytokines in response to blood loss and infection. Dr. Ganz's lecture will also touch upon how, as understanding of systemic iron homeostasis and its disorders increases, biological targets for diagnostic and therapeutic applications will be identified.

Dr. Ganz has been the leading scientist in the effort to uncover the molecular basis of iron homeostasis and its disorders. He played a pivotal role in the discovery of hepcidin and continues to lead the way in the ongoing exploration of hepcidin's effects, regulation, and mechanism of action in iron metabolism. Dr. Ganz's scientific approach is based on diverse, sophisticated, and elegant experimental approaches, ranging from molecular analysis of gene and protein regulation in cell lines and transgenic mice, to histopathologic studies and assays of samples from human patients and experimental animals.

Dr. Ganz currently serves as Professor of Medicine and Pathology at the University of California Los Angeles (UCLA) where he also serves as Director of the Will Rogers Pulmonary Research Laboratory and Co-Director of the Center for Iron Disorders. He earned his PhD in Applied Physics from the California Institute of Technology and his medical degree from UCLA. After completing both his residency in internal medicine and fellowship in pulmonary medicine at UCLA, Dr. Ganz joined the UCLA Department of Medicine in 1983 and has remained there ever since.

The importance of Dr. Ganz's work is evidenced through the publication of his research in many high-impact journals, his involvement in prominent organizations, and his receipt of several prestigious awards. Dr. Ganz is a past president of the International BioIron Society and the recipient of its 2005 Marcel Simon Award for excellence in the research of genetic hemochromatosis. In 2006 he was elected to the American Association of Physicians. Dr. Ganz is also a past recipient of the UCLA Medical Alumni Association Medical Science Award. For many years he served as an Associate Editor of Blood, the journal of the American Society of Hematology.

"Through his discovery of hepcidin and subsequent study of its mechanism of action, Dr. Ganz has revolutionized the field of iron biology and has transformed the way scientists and clinicians study and treat iron and anemia-related diseases," said 2014 ASH President Linda J. Burns, MD, of the University of Minnesota. "ASH is pleased to be honoring Dr. Ganz for his work that has paved the way for development of new treatments for these disorders."


Contact: Amanda Szabo
American Society of Hematology

Related medicine news :

1. Biomarker may identify neuroblastomas with sensitivity to BET bromodomain inhibitors
2. Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture
3. ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement
4. The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice
5. St. Jude Childrens Research Hospital names James R. Downing, M.D., CEO
6. Barry A. Siegel, M.D., receives 2014 Benedict Cassen Prize for Research in Nuclear Medicine
7. Mathuram Santosham, M.D., receives 2014 Albert B. Sabin Gold Medal Award
8. Molly Carnes, M.D., receives inaugural Linda Joy Pollin Heart Health Leadership Award
9. Francis S. Collins, M.D., Ph.D., to speak at AMP 2014 Annual Meeting
10. BIDMCs Martin Pollak, M.D., elected to National Academy of Sciences
11. Boston Medical Center cardiologist Gary Balady, M.D., receives AHAs Paul Dudley White Award
Post Your Comments:
(Date:10/13/2017)... ... , ... PurhealthRX , a leading Health and Nutrition Company, is announcing ... full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the ... incorporated into liquid products, while reducing costs to end users. , The team of ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:10/2/2017)... Oct. 2, 2017 The Rebound mobile app is ... to reverse the tide of prescription drug addiction. The app ... medicine intake and stepping down their dosage in a safe, ... in December 2017; the first 100,000 people to sign up ... ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
Breaking Medicine Technology: